title: Hydrophilic acrylic intraocular lens as a drug-delivery system for fourth-generation fluoroquinolones.
abstract: OBJECTIVE
  To evaluate the ability and safety of a hydrophilic acrylic intraocular lens (IOL) as a drug-delivery system for commercially available gatifloxacin and moxifloxacin.
  
  
  METHODS
  David J. Apple, MD, Laboratories for Ophthalmic Research, John A. Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, Utah, USA.
  
  
  METHODS
  Thirty rabbits were divided into 2 similar groups. In Group A (15 rabbits, 30 eyes), hydrophilic acrylic IOLs (C-flex, Rayner Intraocular Lenses, Ltd.) presoaked for 24 hours in commercially available solutions of gatifloxacin 3 mg/mL or moxifloxacin 5 mg/mL were implanted after evacuation of the crystalline lens. Group B (15 rabbits, 30 eyes) had topical preoperative and postoperative cataract prophylaxis with gatifloxacin 3 mg/mL or moxifloxacin 5 mg/mL; IOLs that were not presoaked were also implanted after evacuation of the crystalline lenses. In both groups, aqueous humor samples were taken 4, 8, or 12 hours after IOL implantation (5 eyes at each time point) to determine the antibiotic concentrations. Clinical examinations were performed 24 hours postoperatively.
  
  
  RESULTS
  The antibiotic concentrations in Group A (presoaked IOLs) were statistically significantly higher than those in Group B (topical) for both antibiotics in all postoperative samples except moxifloxacin at 12 hours. In both groups, there was no statistically significant difference between the concentrations of the 2 antibiotics. No eye showed signs of clinical toxicity.
  
  
  CONCLUSIONS
  Results show the C-flex IOL is a safe and effective drug-delivery system for fourth-generation fluoroquinolones.
authors.affiliation: David J Apple, MD, Laboratories for Ophthalmic Research, John A Moran Eye Center, Department of Ophthalmology and Visual Sciences, University of Utah, Salt Lake City, UT, USA. guy.kleinmann@hsc.utah.edu
authors.forename: Guy
authors.initials: G
authors.lastname: Kleinmann
authors.forename: David J
authors.initials: DJ
authors.lastname: Apple
authors.forename: Jesse
authors.initials: J
authors.lastname: Chew
authors.forename: Brian
authors.initials: B
authors.lastname: Hunter
authors.forename: Scott
authors.initials: S
authors.lastname: Stevens
authors.forename: Scott
authors.initials: S
authors.lastname: Larson
authors.forename: Nick
authors.initials: N
authors.lastname: Mamalis
authors.forename: Randall J
authors.initials: RJ
authors.lastname: Olson
mesh_terms: D000180:Acrylic Resins; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001082:Aqueous Humor / Q000378:metabolism; D001372:Aza Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D016503:Drug Delivery Systems; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077734:Gatifloxacin; D019654:Lens Implantation, Intraocular; D007908:Lens, Crystalline / Q000601:surgery; D007910:Lenses, Intraocular; D000077266:Moxifloxacin; D011804:Quinolines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011817:Rabbits
chemical_list: D000180:Acrylic Resins; D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077734:Gatifloxacin; D000077266:Moxifloxacin